Molecular design of recombinant protein drug
AssigneesTsinghua University, Beijing Protgen Ltd.
InventorsYongzhang Luo, Peng Liu, Xinan Lu
Life of this patent
Estimating the term…
Abstract
Provided is a mutant of an endostatin. The mutant has improved ATPase activity and improved activity of inhibiting angiogenesis and inhibiting tumors. Further provided is use of the mutant in treatment of angiogenesis related diseases such as tumors.
Claims7
A method for increasing the anti-angiogenesis activity of an endostatin or variant thereof, comprising genetically engineering the A motif of the endostatin or variant thereof, to obtain an endostatin mutant with increased ATPase activity compared to the endostatin or variant thereof, wherein said endostatin mutant comprises the sequence set forth in SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.